marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-14-2024
Theravance Biopharma Financial Ratios 2011-2024 | TBPH
Annual Financial Ratios Theravance Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-61.0 | -72.8 | -19.8 | -4.2 | -6.6 | -6.3 | -5.0 | -6.6 | -3.1 | -2.2 | - | - | - |
P/S |
29.6 | 51.5 | 42.3 | 16.2 | 21.2 | 22.5 | 91.8 | 26.0 | 13.3 | 44.1 | - | - | - |
EPS |
-0.2 | -0.1 | -0.4 | -4.5 | -4.2 | -4.0 | -5.5 | -4.3 | -5.3 | -7.5 | -4.9 | -0.3 | - |
EV (Enterprise Value) |
480 M | 456 M | 543 M | 1.08 B | 2.13 B | 1.59 B | 1.65 B | 1.21 B | 505 M | 474 M | 42.2 M | - | - |
EBITDA per Share |
-0.08 | -0.2 | -0.76 | -4.72 | -4.41 | -4.37 | -5.04 | -3.97 | -5.24 | -7.22 | - | - | - |
EV/EBITDA |
-2.1 | -3.8 | -8.0 | -6.1 | -5.9 | -6.4 | -2.5 | -1.9 | - | - | - | ||
PEG |
1.46 | 2.23 | 1.59 | 8.27 | 1.02 | -0.24 | 0.18 | -0.33 | -0.11 | 0.04 | - | - | - |
P/B |
1.4 | 1.2 | 1.7 | 2.5 | -6.9 | -26.3 | 12.3 | 3.6 | 2.3 | 1.8 | - | - | - |
P/CF |
-19.2 | -4.0 | -3.0 | -4.6 | -6.4 | -11.3 | -6.9 | -12.5 | -3.3 | -2.9 | - | - | - |
ROE % |
-4.00 | -2.35 | 9.46 | 91.53 | 105.64 | 417.77 | -247.79 | -54.44 | -74.97 | -81.80 | - | - | - |
ROA % |
-2.23 | -1.71 | -8.55 | -59.27 | -57.84 | -38.47 | -64.66 | -29.83 | -60.72 | -70.18 | - | - | - |
ROCE % |
-2.93 | -3.95 | 16.59 | 97.98 | -84.78 | -51.71 | -70.77 | -30.59 | -72.57 | -78.42 | - | - | - |
Current Ratio |
- | - | - | - | 3.0 | 5.4 | 6.1 | 10.7 | 4.8 | 6.7 | - | - | - |
DSO |
- | - | - | - | 251.4 | 64.5 | 222.1 | 72.9 | 321.9 | 66.5 | - | - | - |
DIO |
- | - | - | - | - | - | 1018.7 | 1541.2 | 784.2 | 1128.5 | - | - | - |
DPO |
- | - | - | - | - | 4608.7 | 358.6 | 218.6 | 1473.8 | 892.4 | - | - | - |
Operating Cycle |
- | - | - | - | - | 64.5 | 1240.8 | 1614.2 | 1106.1 | 1194.9 | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | -4544.2 | 882.2 | 1395.6 | -367.7 | 302.6 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Theravance Biopharma
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.26 | -0.34 | -0.24 | - | -0.17 | -0.28 | -0.35 | - | 12.14 | -0.11 | -0.34 | -0.43 | -0.48 | -0.8 | -1.24 | -0.92 | -1.16 | -1 | -1.4 | -1.17 | -1.05 | -0.72 | -1.32 | -0.92 | -1.1 | -0.76 | -1.22 | -1.64 | -1.27 | -1.27 | -1.27 | -1.36 | -0.73 | -1.06 | -1.1 | -1.23 | -1.4 | -1.42 | -1.29 | -2.02 | -1.72 | -1.83 | -1.89 | -1.39 | -1.29 | -1.23 | -1.01 | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | - | - | -0.19 | -0.3 | -0.49 | -0.75 | -0.73 | -0.98 | -1.3 | -1.19 | -1.21 | -1.14 | -1.21 | -1.24 | -1.15 | -0.75 | -1.3 | -1.12 | -1.13 | -0.89 | -1.2 | -1.46 | -1.03 | -1.21 | -1.12 | -1.09 | -0.68 | -1.04 | -1.07 | -1.47 | -1.21 | -1.3 | -1.12 | -2.04 | -1.5 | -1.74 | -1.87 | - | -1.23 | -1.18 | - | - | - | - | - | - | - | - | - |
ROE % |
-24.70 | -21.50 | -18.55 | -15.18 | 175.55 | 369.93 | 377.85 | 200.46 | 209.92 | 30.10 | 45.20 | 59.17 | 68.94 | 82.28 | 85.53 | 91.53 | 101.60 | 103.46 | 100.55 | 105.64 | 173.61 | 262.71 | 324.03 | 417.77 | 245.02 | 71.75 | -64.92 | -247.79 | -191.55 | -143.19 | -99.12 | -54.44 | -53.66 | -63.43 | -69.53 | -74.97 | -78.72 | -78.06 | -78.56 | -81.80 | 199.16 | 459.10 | 707.85 | 917.43 | 658.67 | 417.53 | 188.87 | - | - | - | - | - | - | - | - |
ROA % |
-13.44 | -12.03 | -10.97 | -9.77 | 110.29 | 232.51 | 233.74 | 110.49 | 101.94 | -26.88 | -36.82 | -50.76 | -54.67 | -61.61 | -62.81 | -59.27 | -62.86 | -61.45 | -57.79 | -57.84 | -50.75 | -47.06 | -44.61 | -38.47 | -49.20 | -53.75 | -61.48 | -64.66 | -55.50 | -45.66 | -38.03 | -29.83 | -34.23 | -44.68 | -53.16 | -60.72 | -64.82 | -65.19 | -66.56 | -70.18 | -226.22 | -373.24 | -510.72 | -620.74 | -445.66 | -282.50 | -127.79 | - | - | - | - | - | - | - | - |
ROCE % |
-22.98 | -20.70 | -18.34 | -16.04 | -18.99 | -18.39 | -6.03 | 14.24 | 30.83 | 50.35 | 65.09 | 76.98 | 85.57 | 94.23 | 96.64 | 98.03 | 104.37 | 108.28 | 103.49 | 112.54 | 202.40 | 294.32 | 369.76 | 462.79 | 272.67 | 102.13 | -48.82 | -225.84 | -173.62 | -133.69 | -90.71 | -51.53 | -57.96 | -66.13 | -71.20 | -74.84 | -74.58 | -74.13 | -75.06 | -80.24 | 201.21 | 459.62 | 707.85 | 917.43 | 658.67 | 417.53 | 188.87 | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.7 | 0.4 | 6.3 | 3.6 | 4.4 | 2.4 | 15.8 | 45.5 | 48.1 | 58.6 | 42.9 | 10.4 | 3.1 | 10.8 | 6.4 | 45.0 | 16.4 | 24.6 | 4.9 | 18.4 | 4.2 | 8.9 | 23.6 | 103.8 | 756.6 | 3631.8 | 412.7 | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.7 | 0.4 | 6.3 | 3.6 | 4.4 | 2.4 | 15.8 | 45.5 | 48.1 | 58.6 | 42.9 | 10.4 | 3.1 | 10.8 | 6.4 | 45.0 | 16.4 | 24.6 | 4.9 | 18.4 | 4.2 | 8.9 | 23.6 | 103.8 | 756.6 | 3631.8 | 412.7 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.7 | 0.4 | 6.3 | 3.6 | 4.4 | 2.4 | 15.8 | 45.5 | 48.1 | 58.6 | 42.9 | 10.4 | 3.1 | 10.8 | 6.4 | 45.0 | 16.4 | 24.6 | 4.9 | 18.4 | 4.2 | 8.9 | 23.6 | 103.8 | 756.6 | 3631.8 | 412.7 | - | - | - | - | - | - | - | - |
All numbers in USD currency